Demonstrate Exubera Works As Well As Avandia When Added To Sulfonylurea + Metformin In Controlling Glucose

NCT ID: NCT00150410

Last Updated: 2008-10-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

626 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-01-31

Study Completion Date

2007-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

* Whether a combination of three therapies - metformin and a sulfonylurea plus Exubera, an investigational drug, controls your diabetes at least as much as a triple combination therapy of metformin and a sulfonylurea plus Avandia, a Food and Drug Administration (FDA) approved drug.
* Whether a combination of two therapies - metformin plus Exubera controls your diabetes at least as much as a as a triple combination therapy of metformin and a sulfonylurea plus Avandia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Inhaled insulin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Type 2 diabetes
* Currently treated and on a stable doses of drugs for the preceding two (2) months

Exclusion Criteria

* Type 1 Diabetes
* Smoking
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sanofi

INDUSTRY

Sponsor Role collaborator

Pfizer

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Mesa, Arizona, United States

Site Status

Pfizer Investigational Site

Phoenix, Arizona, United States

Site Status

Pfizer Investigational Site

Tucson, Arizona, United States

Site Status

Pfizer Investigational Site

Searcy, Arkansas, United States

Site Status

Pfizer Investigational Site

Alhambra, California, United States

Site Status

Pfizer Investigational Site

Concord, California, United States

Site Status

Pfizer Investigational Site

Huntington Beach, California, United States

Site Status

Pfizer Investigational Site

Huntington Beach, California, United States

Site Status

Pfizer Investigational Site

La Jolla, California, United States

Site Status

Pfizer Investigational Site

Long Beach, California, United States

Site Status

Pfizer Investigational Site

Long Beach, California, United States

Site Status

Pfizer Investigational Site

Los Angeles, California, United States

Site Status

Pfizer Investigational Site

Riverside, California, United States

Site Status

Pfizer Investigational Site

Santa Barbara, California, United States

Site Status

Pfizer Investigational Site

Tustin, California, United States

Site Status

Pfizer Investigational Site

Westminster, California, United States

Site Status

Pfizer Investigational Site

Denver, Colorado, United States

Site Status

Pfizer Investigational Site

Wheat Ridge, Colorado, United States

Site Status

Pfizer Investigational Site

Waterbury, Connecticut, United States

Site Status

Pfizer Investigational Site

Washington D.C., District of Columbia, United States

Site Status

Pfizer Investigational Site

Washington D.C., District of Columbia, United States

Site Status

Pfizer Investigational Site

Hollywood, Florida, United States

Site Status

Pfizer Investigational Site

West Palm Beach, Florida, United States

Site Status

Pfizer Investigational Site

Winter Park, Florida, United States

Site Status

Pfizer Investigational Site

Atlanta, Georgia, United States

Site Status

Pfizer Investigational Site

Augusta, Georgia, United States

Site Status

Pfizer Investigational Site

Savannah, Georgia, United States

Site Status

Pfizer Investigational Site

Savannah, Georgia, United States

Site Status

Pfizer Investigational Site

Honolulu, Hawaii, United States

Site Status

Pfizer Investigational Site

‘Ewa Beach, Hawaii, United States

Site Status

Pfizer Investigational Site

Idaho Falls, Idaho, United States

Site Status

Pfizer Investigational Site

Idaho Falls, Idaho, United States

Site Status

Pfizer Investigational Site

Chicago Heights, Illinois, United States

Site Status

Pfizer Investigational Site

Indianapolis, Indiana, United States

Site Status

Pfizer Investigational Site

Des Moines, Iowa, United States

Site Status

Pfizer Investigational Site

Wichita, Kansas, United States

Site Status

Pfizer Investigational Site

Lexington, Kentucky, United States

Site Status

Pfizer Investigational Site

Louisville, Kentucky, United States

Site Status

Pfizer Investigational Site

Baton Rouge, Louisiana, United States

Site Status

Pfizer Investigational Site

New Orleans, Louisiana, United States

Site Status

Pfizer Investigational Site

Baltimore, Maryland, United States

Site Status

Pfizer Investigational Site

Springfield, Massachusetts, United States

Site Status

Pfizer Investigational Site

Springfield, Massachusetts, United States

Site Status

Pfizer Investigational Site

Waltham, Massachusetts, United States

Site Status

Pfizer Investigational Site

West Saint Paul, Minnesota, United States

Site Status

Pfizer Investigational Site

North Kansas City, Missouri, United States

Site Status

Pfizer Investigational Site

St Louis, Missouri, United States

Site Status

Pfizer Investigational Site

Butte, Montana, United States

Site Status

Pfizer Investigational Site

Lincoln, Nebraska, United States

Site Status

Pfizer Investigational Site

New Brunswick, New Jersey, United States

Site Status

Pfizer Investigational Site

New Brunswick, New Jersey, United States

Site Status

Pfizer Investigational Site

Albuquerque, New Mexico, United States

Site Status

Pfizer Investigational Site

Albany, New York, United States

Site Status

Pfizer Investigational Site

Flushing, New York, United States

Site Status

Pfizer Investigational Site

Mineola, New York, United States

Site Status

Pfizer Investigational Site

New Hyde Park, New York, United States

Site Status

Pfizer Investigational Site

Rochester, New York, United States

Site Status

Pfizer Investigational Site

Raleigh, North Carolina, United States

Site Status

Pfizer Investigational Site

Cincinnati, Ohio, United States

Site Status

Pfizer Investigational Site

Cleveland, Ohio, United States

Site Status

Pfizer Investigational Site

Lakewood, Ohio, United States

Site Status

Pfizer Investigational Site

Oklahoma City, Oklahoma, United States

Site Status

Pfizer Investigational Site

Portland, Oregon, United States

Site Status

Pfizer Investigational Site

Pittsburgh, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Charleston, South Carolina, United States

Site Status

Pfizer Investigational Site

Charleston, South Carolina, United States

Site Status

Pfizer Investigational Site

Duncan, South Carolina, United States

Site Status

Pfizer Investigational Site

Spartanburg, South Carolina, United States

Site Status

Pfizer Investigational Site

Spartanburg, South Carolina, United States

Site Status

Pfizer Investigational Site

Sumter, South Carolina, United States

Site Status

Pfizer Investigational Site

Kingsport, Tennessee, United States

Site Status

Pfizer Investigational Site

Knoxville, Tennessee, United States

Site Status

Pfizer Investigational Site

Memphis, Tennessee, United States

Site Status

Pfizer Investigational Site

Nashville, Tennessee, United States

Site Status

Pfizer Investigational Site

Corpus Christi, Texas, United States

Site Status

Pfizer Investigational Site

Dallas, Texas, United States

Site Status

Pfizer Investigational Site

Dallas, Texas, United States

Site Status

Pfizer Investigational Site

El Paso, Texas, United States

Site Status

Pfizer Investigational Site

El Paso, Texas, United States

Site Status

Pfizer Investigational Site

San Antonio, Texas, United States

Site Status

Pfizer Investigational Site

San Antonio, Texas, United States

Site Status

Pfizer Investigational Site

Ogden, Utah, United States

Site Status

Pfizer Investigational Site

Fredericksburg, Virginia, United States

Site Status

Pfizer Investigational Site

Richmond, Virginia, United States

Site Status

Pfizer Investigational Site

Richmond, Virginia, United States

Site Status

Pfizer Investigational Site

Renton, Washington, United States

Site Status

Pfizer Investigational Site

Tukwila, Washington, United States

Site Status

Pfizer Investigational Site

Milwaukee, Wisconsin, United States

Site Status

Pfizer Investigational Site

Camperdown, New South Wales, Australia

Site Status

Pfizer Investigational Site

Wollongong, New South Wales, Australia

Site Status

Pfizer Investigational Site

Herston, Queensland, Australia

Site Status

Pfizer Investigational Site

Woolloongabba, Queensland, Australia

Site Status

Pfizer Investigational Site

Keswick, South Australia, Australia

Site Status

Pfizer Investigational Site

Box Hill, Victoria, Australia

Site Status

Pfizer Investigational Site

Caulfield, Victoria, Australia

Site Status

Pfizer Investigational Site

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Pfizer Investigational Site

São Paulo, São Paulo, Brazil

Site Status

Pfizer Investigational Site

São Paulo, São Paulo, Brazil

Site Status

Pfizer Investigational Site

Winnipeg, Manitoba, Canada

Site Status

Pfizer Investigational Site

London, Ontario, Canada

Site Status

Pfizer Investigational Site

Mississauga, Ontario, Canada

Site Status

Pfizer Investigational Site

Oakville, Ontario, Canada

Site Status

Pfizer Investigational Site

Thornhill, Ontario, Canada

Site Status

Pfizer Investigational Site

Toronto, Ontario, Canada

Site Status

Pfizer Investigational Site

Toronto, Ontario, Canada

Site Status

Pfizer Investigational Site

Laval, Quebec, Canada

Site Status

Pfizer Investigational Site

Montreal, Quebec, Canada

Site Status

Pfizer Investigational Site

Saint-Jérôme, Quebec, Canada

Site Status

Pfizer Investigational Site

Vaudreuil, Quebec, Canada

Site Status

Pfizer Investigational Site

St. John's, , Canada

Site Status

Pfizer Investigational Site

Guadalajara, Jalisco, Mexico

Site Status

Pfizer Investigational Site

Guadalajara, Jalisco, Mexico

Site Status

Pfizer Investigational Site

Guadalajara, Jalisco, Mexico

Site Status

Pfizer Investigational Site

Guadalajara, Jalisco/Mexico, Mexico

Site Status

Pfizer Investigational Site

Mexico City, Mexico City, Mexico

Site Status

Pfizer Investigational Site

Mexico City, Mexico City, Mexico

Site Status

Pfizer Investigational Site

Monterrey, Nuevo León, Mexico

Site Status

Pfizer Investigational Site

Jalapa, Veracruz, Mexico

Site Status

Pfizer Investigational Site

Mexico City, , Mexico

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Brazil Canada Mexico

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A2171017

Identifier Type: -

Identifier Source: org_study_id